Lauren V. Wood, M.D.
Dr. Wood retired on August 1, 2017. Please direct your inquiries to the following members of the Vaccine Branch Clinical Trials Team:
Dr. Wood served as Director of the Branch's clinical translational research program from 2005 until her retirement. Her clinical research interests included therapeutic vaccines and immune-based therapies for cancer and HIV infection, as well as approaches to prevent the malignant complications associated with chronic viral infections such as human papilloma virus (HPV) and hepatitis C. She also conducted research into HIV and HPV transmission knowledge and risk behaviors associated with their acquisition.
The mission of the Vaccine Branch clinical research program is to develop vaccines and immune-based therapies that harness the immune response to control, eradicate or prevent cancer and human immunodeficiency virus (HIV) infection. Our vision is that through the use of immunotherapeutic agents we will:
- Improve the efficacy of chemotherapy regimens and eliminate micrometastatic disease in patients with cancer.
- Reduce or eliminate the need for chronic administration of antiretroviral agents in patients with HIV infection.
Dr. Wood's clinical research interests included therapeutic vaccines and immune-based therapies for cancer and HIV infection, as well as approaches to prevent the malignant complications associated with chronic viral infections such as human papilloma virus (HPV) and hepatitis C. She also conducted research into HIV and HPV transmission knowledge and risk behaviors associated with their acquisition.
Selected Recent Publications
Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.Clin Cancer Res. 23(13): 3352-3364, 2017. [ Journal Article ]
Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Antimicrob Agents Chemother. 61(2): e01477-16, 2017. [ Journal Article ]
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Oncoimmunology. 5(8): e1197459, 2016. [ Journal Article ]
Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.J Nucl Med. 57(6): 886-92, 2016. [ Journal Article ]
Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.J Immunol. 194(9): 4215-21, 2015. [ Journal Article ]
Dr. Lauren V. Wood is a board certified Allergist/Immunologist and Head of the Vaccine Branch Clinical Trials Team. She earned her B.A. degree in biology from Oberlin College and her M.D. from Duke University School of Medicine. She completed a combined residency in internal medicine and pediatrics at Baylor College of Medicine Affiliated Hospitals in Houston, TX, and became board certified in both specialties. Dr. Wood then came to the National Institute of Allergy and Infectious Diseases (NIAID) for a fellowship in allergy and immunology and spent two years in the laboratory of Dr. Anthony Fauci investigating HIV-specific cellular and humoral immune responses.
Following completion of her fellowship, she worked for a year with Drs. Henry Masur and H. Clifford Lane in the NIAID HIV/AIDS Clinical Research Program before being recruited to the NCI in 1992 by Dr. Philip Pizzo. As a member of the senior staff of the Pediatric HIV Working Group initially under Dr. Pizzo and subsequently under Dr. Robert Yarchoan, her clinical research focused on the investigation of antiretroviral agents and immune-based therapies in HIV-infected children, adolescents, and young adults, including the initial studies of lamivudine (3TC) and ritonavir that led to FDA approval for their use in children. Dr. Wood also conducted studies of recombinant IL-2 , HIV therapeutic vaccines and adherence to antiretroviral treatment in addition to investigating the infectious, malignant and psychosocial complications of pediatric HIV disease in collaboration with other NCI colleagues.
In 2005 Dr. Wood joined the newly formed Vaccine Branch and was charged with developing a clinical translational research program, which she directed until her retirement. Dr. Wood is an Assistant Professor at the Uniformed Services University of the Health Sciences and is a Captain in the U.S. Public Health Service. She has served on multiple Food and Drug Administration (FDA), White House and other interagency advisory, review and data safety monitoring committees, in addition to the publication and invited presentation of her work at national and international scientific meetings.